Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
IPO Year: 2021
Exchange: NASDAQ
Website: pharvaris.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/25/2023 | $27.00 | Outperform | Wedbush |
| 8/15/2023 | $10.00 → $34.00 | Equal-Weight → Overweight | Morgan Stanley |
| 10/5/2022 | $16.00 | Buy | Bryan Garnier |
| 9/13/2022 | $34.00 → $18.00 | Mkt Outperform | JMP Securities |
| 8/23/2022 | $40.00 → $10.00 | Overweight → Equal-Weight | Morgan Stanley |
| 8/22/2022 | $26.00 → $13.00 | Neutral → Underperform | BofA Securities |
| 5/25/2022 | $34.00 | Mkt Outperform | JMP Securities |
6-K - Pharvaris N.V. (0001830487) (Filer)
6-K - Pharvaris N.V. (0001830487) (Filer)
6-K - Pharvaris N.V. (0001830487) (Filer)
144 - Pharvaris N.V. (0001830487) (Subject)
144 - Pharvaris N.V. (0001830487) (Subject)
6-K - Pharvaris N.V. (0001830487) (Filer)
144 - Pharvaris N.V. (0001830487) (Subject)
144 - Pharvaris N.V. (0001830487) (Subject)
144 - Pharvaris N.V. (0001830487) (Subject)
144 - Pharvaris N.V. (0001830487) (Subject)
CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece
Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo92.3% reduction in occurrence of moderate and severe attacks92.6% fewer attacks treated with on-demand medication by participantsDeucrictibant well-toleratedPharvaris to host a conference call today at 8:00 a.m. EST ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoi
Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks. Pharvaris plans to present data from the study at future medical meetings. RAPIDe-1 Clinical Stu
Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congressesIntend to engage in clinical development of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH)Initiation of CHAPTER-3 global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment of HAE using once-daily extended-release tablet expected by YE2024Operating from a strong financial position with cash and cash equivalents of €305 million as of September 30, 2024 ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biop
ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced that its management will participate in the Inaugural Guggenheim Securities Healthcare Innovation Conference, taking place from November 11-13, 2024, at the InterContinental Boston. Details are as follows: Format: Fireside ChatDate, time: Wednesday, November 13, 9:30 a.m. ET Webcast Link A live audio webcast will also be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.
-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
ZUG, Switzerland, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced data from seven posters that will be presented at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). Pharvaris mourns our distinguished colleague, Prof. Marcus Maurer, who passed away during the development and finalization of these posters. "The totality of data supporting deucrictibant's potential best-in-class profile in both prophylaxis and on-demand remains consistent and provides compelling
ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows: American College of Allergy, Asthma, & Immunology's Annual Scientific Meeting (ACAAI), Boston, October 24-28, 2024. Seven abstracts have been accepted for e-Poster presentation: Poster: Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: CHAPTER-1 Open-Label Extension StudySpeaker: John Anders
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced it will host a virtual investor event to discuss the unmet need in both the prophylactic and on-demand treatment of HAE attacks, the potential of deucrictibant to address to needs, and the current HAE market dynamics, on Wednesday, October 23, 2024, at 10:00 a.m. ET/16:00 CET. To register, click here. Presenters of the event are: Michael E. Manning, M.D., Allergy, Asthma & Immunology Associates, LTDRaffi Tachdjian, M.D., MPH, David Geffen Schoo
ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of six abstracts, two for oral presentation and four for poster presentation, at the 2024 Global Angioedema Forum – HAEi Global Leadership Workshop, taking place in Copenhagen, Denmark, from Oct. 4-5, 2024. Details are as follows: Title: Long-Term Safety and Efficacy of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension StudyPresenter: Ma
CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece
Extension data confirm the observed safety and tolerability profile from Phase 2 studies and further support the potential for deucrictibant to become a preferred therapy for the management of HAELong-term prophylaxis extension data of deucrictibant shows attack reduction is maintained for over one year; open-label extension participants experienced a 93% reduction in attacks compared to baselineLong-term on-demand extension data of deucrictibant immediate-release capsule shows median onset of symptom relief in ~1.1 hours, with 85.8% of attacks resolving completely within 24 hours ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical
ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced a summary of data being presented at the ongoing 7th Bradykinin Symposium. Details of the presentations are outlined below: Long-Term Safety and Efficacy of Oral Deucrictibant for HAE Prophylaxis, a poster presentation by Marc A. Riedl, M.D., M.S. In the current analysis of the ongoing open-label extension of the CHAPTER-1 Phase 2 study, deucrictibant 40 mg/day was well-tolerated, with no new safety signals observed. The results presented provi
Oppenheimer analyst Justin Kim maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $36 to $38.
Wedbush analyst Laura Chico maintains Pharvaris (NASDAQ:PHVS) with a Outperform and lowers the price target from $35 to $31.
Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and maintains $34 price target.
Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and lowers the price target from $35 to $34.
- SEC Filing
JMP Securities analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and raises the price target from $49 to $50.
Wedbush analyst Laura Chico reiterates Pharvaris (NASDAQ:PHVS) with a Outperform and maintains $35 price target.
Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.58) by 37.93 percent. This is a 32.2 percent increase over losses of $(1.18) per share from the same period last year.
SC 13G/A - Pharvaris N.V. (0001830487) (Subject)
SC 13G/A - Pharvaris N.V. (0001830487) (Subject)
SC 13G/A - Pharvaris N.V. (0001830487) (Subject)
SC 13G/A - Pharvaris N.V. (0001830487) (Subject)
SC 13G/A - Pharvaris N.V. (0001830487) (Subject)
SC 13G/A - Pharvaris N.V. (0001830487) (Subject)
SC 13G/A - Pharvaris N.V. (0001830487) (Subject)
SC 13G - Pharvaris N.V. (0001830487) (Subject)
SC 13G/A - Pharvaris N.V. (0001830487) (Subject)
SC 13G/A - Pharvaris N.V. (0001830487) (Subject)
Wedbush initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $27.00
Morgan Stanley upgraded Pharvaris N.V. from Equal-Weight to Overweight and set a new price target of $34.00 from $10.00 previously
Bryan Garnier initiated coverage of Pharvaris N.V. with a rating of Buy and set a new price target of $16.00
JMP Securities resumed coverage of Pharvaris N.V. with a rating of Mkt Outperform and set a new price target of $18.00 from $34.00 previously
Morgan Stanley downgraded Pharvaris N.V. from Overweight to Equal-Weight and set a new price target of $10.00 from $40.00 previously
BofA Securities downgraded Pharvaris N.V. from Neutral to Underperform and set a new price target of $13.00 from $26.00 previously
JMP Securities initiated coverage of Pharvaris N.V. with a rating of Mkt Outperform and set a new price target of $34.00
SVB Leerink initiated coverage of Pharvaris with a rating of Outperform and set a new price target of $50.00
Morgan Stanley resumed coverage of Pharvaris with a rating of Overweight and set a new price target of $51.00
Oppenheimer initiated coverage of Pharvaris with a rating of Outperform and set a new price target of $48.00
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities
Formal letters received from FDA relating to the previously announced hold on clinical studies of PHA121 in the U.S.Top-line data anticipated in 4Q22 for RAPIDe-1, a global Phase 2 study of PHVS416 for the acute treatment of HAE attacks ongoing outside the U.S.Executing from a strong financial position with cash and cash equivalents of €201 million as of June 30, 2022 ZUG, Switzerland, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the second quarter ended June 30, 2022, and provided a business update
Pharvaris' executive team further strengthened by Ms. Schmidt's deep international experience and biopharmaceutical industry tenure ZUG, Switzerland, May 11, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced the appointment of Joan Schmidt, J.D., to the newly created position of Chief Legal Officer, effective June 1, 2022. In this role, she will lead all legal activities, including compliance and governance, in support of Pharvaris' clinical drug development and commercialization strategies.
ZUG, Switzerland, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the appointment of Anne Marie de Jonge Schuermans, Ph.D., to the board of directors with expected confirmation at the company's 2022 annual general meeting of shareholders. Dr. de Jonge Schuermans will replace Rémi Droller, who has stepped down from the board effective Dec. 22, 2021, to focus on new investments. "Anne Marie is a tremendous addition to our board," said David
ZUG, Switzerland, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the appointment of Elisabeth Björk, M.D., to the board of directors with expected confirmation at the company's 2022 annual general meeting of shareholders. Dr. Björk will replace Martijn Kleijwegt, who has stepped down from the board effective December 1 to focus on new investments. "Elisabeth is joining the Pharvaris board at an important time for the company as we prepare
RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks expanding to US, expected to report data in 2022 CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of HAE attacks, and PHVS719 Phase 1 PK study expected to initiate in 2021Executing from a strong financial position with cash and cash equivalents of €224.3 million as of June 30, 2021 ZUG, Switzerland, July 30, 2021 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today report